Bank of Nova Scotia Purchases Shares of 131,985 Stryker Corporation $SYK

Bank of Nova Scotia acquired a new position in Stryker Corporation (NYSE:SYK - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 131,985 shares of the medical technology company's stock, valued at approximately $41,554,000.

A number of other institutional investors and hedge funds have also modified their holdings of SYK. Vanguard Group Inc. boosted its holdings in Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company's stock valued at $11,917,396,000 after purchasing an additional 133,892 shares in the last quarter. State Street Corp raised its holdings in shares of Stryker by 2.1% in the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company's stock worth $5,374,731,000 after buying an additional 311,507 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Stryker by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company's stock worth $2,636,238,000 after buying an additional 69,851 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company's stock worth $2,282,192,000 after buying an additional 1,198,665 shares during the period. Finally, Norges Bank bought a new position in shares of Stryker during the 4th quarter worth approximately $1,822,272,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Trading Up 0.1%

Shares of NYSE SYK opened at $329.86 on Monday. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The company has a 50-day moving average of $326.99 and a two-hundred day moving average of $332.39. The company has a market cap of $126.52 billion, a PE ratio of 34.18, a P/E/G ratio of 2.10 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker's revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts expect that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker's dividend payout ratio is currently 36.48%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on SYK. UBS Group began coverage on Stryker in a research report on Tuesday, July 28th. They issued a "buy" rating and a $400.00 price target on the stock. Wolfe Research cut Stryker from an "outperform" rating to a "peer perform" rating in a report on Thursday, August 13th. Argus set a $370.00 target price on shares of Stryker in a research note on Thursday, July 9th. Canaccord Genuity Group lowered their target price on shares of Stryker from $435.00 to $400.00 and set a "buy" rating on the stock in a report on Friday, May 1st. Finally, Robert W. Baird set a $385.00 target price on shares of Stryker in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Stryker has a consensus rating of "Moderate Buy" and an average target price of $386.28.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 50,000 shares of Stryker stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the sale, the director directly owned 2,251,375 shares of the company's stock, valued at $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Robert S. Fletcher sold 4,544 shares of the company's stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares of the company's stock, valued at $3,247,298.34. This represents a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 665,370 shares of company stock worth $216,238,501. Insiders own 4.60% of the company's stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source